Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2204683
下载链接
链接失效反馈官方服务：
资源简介：
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin’s lymphoma (NHL).
创建时间：
2016-02-15
